No increased risk of symptomatic intracerebral hemorrhage after thrombolysis in patients with European Cooperative Acute Stroke Study (ECASS) exclusion criteria

Stroke

Volumn 43, Issue 6, 2012, Pages 1684-1686

  Cronin, Carolyn A ^a   Shah, Nikeith ^a   Morovati, Tanya ^b   Hermann, Lisa D ^c   Sheth, Kevin N ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

acute stroke; exclusion criteria; thrombolysis

Indexed keywords

GLUCOSE; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

AGE DISTRIBUTION; AGED; ARTICLE; BLOOD CLOT LYSIS; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; DIABETES MELLITUS; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MORTALITY; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

ACUTE DISEASE; AGED, 80 AND OVER; ANTIFIBRINOLYTIC AGENTS; EUROPE; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84861603634     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.656587     Document Type: Article

References (8)

1. Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke. 2008;39:924-928.
2. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility. Neurology. 2001;56:1015-1020.
3. California Acute Stroke Pilot Registry (CASPR) Investigators. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology. 2005;64:654-659.
4. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
5. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr, American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40:2945-2948.
6. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Generalized efficacy of tPA for acute stroke. Subgroup analysis of the NINDS tPA Stroke Trial. Stroke. 1997;28: 2119-2125.
7. Rubiera M, Ribo M, Santamarina E, Maisterra O, Delgado-Mederos R, Delgado P, et al. Is it time to reassess the SITS-MOST criteria for thrombolysis? A comparison of patients with and without SITS-MOST exclusion criteria. Stroke. 2009;40:2568-2571.
8. Meretoja A, Putaala J, Tatlisumak T, Atula S, Artto V, Curtze S, et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke. 2010;41:1450-1458.